• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senate panel to investigate Mylan’s EpiPen pricing

September 8, 2016 By Sarah Faulkner

Mylan's EpiPenThe U.S. Senate’s investigations panel is reportedly launching a “preliminary inquiry” into Mylan’s (NSDQ:MYL) pricing of the EpiPen epinephrine auto-injector.

Mylan came under fire in recent weeks for raising the price of EpiPens nearly 500%, from $100 in 2008 to more than $500 this year, despite stable manufacturing costs. In late August, Sens. Amy Klobuchar (D-Minn.) and Charles Grassley (R-Iowa) pressed Mylan to release a cost analysis of the device. Klobuchar also penned a letter to the U.S. Federal Trade Commission to investigate whether Mylan violated antitrust laws.

Yesterday, in a prepared statement, Sens. Rob Portman (R-Ohio), chairman of the investigations subcommittee, and Claire McCaskill (D-Miss.), its top Democrat, said, “Our review of this matter will be robust, thorough and bipartisan. Parents and school districts in Ohio, Missouri and across the country need affordable access to this life-saving drug, and we share their concern over Mylan’s sustained price increases.”

Mylan CEO Heather Bresch maintains that the cost increases are justified because of improvements Mylan made to the device. Bresch cites the “complexity and opaqueness of today’s branded pharmaceutical supply chain” as a motivation for companies to increase their prices.

Mylan said in late August that it would expand existing patient support programs and develop a generic that would cost around $300 for a pair of injectors. Rep. Elijah Cummings (D-Md.) called the move nothing more than a public relations stunt.

Mylan’s shares dropped 10% to $42.64 apiece when the criticism began in August. Since then, shares have slowly but steadily declined. The stock was trading at $40.12 per share in mid-morning activity today, down 0.47%.

Filed Under: Drug-Device Combinations, Wall Street Beat Tagged With: Capitol Hill, Mylan

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS